Results 161 to 170 of about 2,437,835 (277)

The Value of Using Bedside Point of Care Testing for International Normalized Ratio in Patients on Warfarin Undergoing Dental Procedures and Bleeding Assessment; A Single Center Prospective Study

Journal of Blood Medicine
Abdullah Albarkheel,1 Hawazen Alshareef,1 Amal Albar,1 Sohayla Youssef Altbaili,1 Mohammed Ali Alminaqash,1 Amjad Alotibie,2 Aamir Sheikh,3,4 Abdullah Alahmadi,3 Badar Alaifan,3 Hani Tamim,4 Tarek Owaidah2,4 1Dental Department, King Faisal Specialist ...
Albarkheel A, Alshareef H, Albar A, Altbaili SY, Alminaqash MA, Alotibie A, Sheikh A, Alahmadi A, Alaifan B, Tamim H, Owaidah T   +10 more
doaj  

Policymaker Perspectives on the Role of Health Systems in Sustainable Hepatitis C Point-Of-Care Testing in Australia. [PDF]

J Viral Hepat
Conway A, Grebely J, Treloar C, Matthews S, Lafferty L, Taylor N, Fontaine G, Marshall AD.   +7 more
europepmc   +1 more source

ATF4‐mediated stress response as a therapeutic vulnerability in chordoma

Molecular Oncology, EarlyView.
We screened 5 chordoma cell lines against 100+ inhibitors of epigenetic and metabolic pathways and kinases and identified halofuginone, a tRNA synthetase inhibitor. Mechanistically halofuginone induces an integrated stress response, with eIF2alpha phosphorylation, activation of ATF4 and its target genes CHOP, ASNS, INHBE leading to cell death ...
Lucia Cottone, James Dunford, Eleanor Calcutt, Vicki Gamble, Filiz Senbabaoglu Aksu, Lorena Ligammari, Georgina Wherry, Giorgia Gaeta, John C. Christianson, Adrienne M. Flanagan, Udo Oppermann, Adam P. Cribbs   +11 more
wiley   +1 more source

A Molecularly Imprinted Membrane for High-Density Lipoprotein Extraction in Point-of-Care Testing. [PDF]

Biosensors (Basel)
de Gregorio GL, Prim D, Zavattoni A, Mottini I, Pezzoli D, Roveda F, Pfeifer ME, Segura JM.   +7 more
europepmc   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source

Long-term real-world performance of the Bayer Contour TS point-of-care testing glucose meters. [PDF]

Sci Rep
Zhao Z, Lang Y, Wang T, Zhao X, Li R, Li X, Xiong P, Li R.   +7 more
europepmc   +1 more source

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

Molecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken, Andrea Abel Gutierrez, Imke van Rossum, Cornelia G. Spruijt, Michiel Vermeulen, Guido van Mierlo, Blanca Scheijen, Annemiek B. van Spriel   +7 more
wiley   +1 more source

Point-of-Care Testing and Biomarkers in Biliary Diseases: Current Evidence and Future Directions. [PDF]

J Clin Med
Jung JH, Lee KJ, Park SW, Koh DH, Lee J.
europepmc   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Transformative impact of point-of-care testing in critical care. [PDF]

World J Crit Care Med
Dabla PK, Dabas A.
europepmc   +1 more source